Tofersen sodium
Based on 2 publication(s) in Google Scholar
Tofersen (BIIB067) sodium is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen sodium mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen sodium downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen sodium can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.55%
- CAS 番号: 1898254-60-8
- 分子式: C230H298N72Na19O123P19S15
- 分子量:7128 (free acid)
-
保管条件:
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Tofersen sodium
More
生物活性
|
SOD mRNA 0.32 nM (IC50) |
Tofersen (72 h) sodium potently silences SOD1 mRNA in human HeLa cells with an IC50 of ~0.32 nM[2].
Tofersen sodium-loaded Ca2+P lipid nanoparticles (72 h) reduce SOD1 protein levels by >3.3-fold in HEK293T cells after 72 h of incubation[5].
Tofersen sodium-loaded Ca2+P lipid nanoparticles (0.78-50 nM; 1-48 h) exhibit dose- and time-dependent uptake into NSC-34 mouse motor neuron-like cells, are non-cytotoxic at concentrations up to 25 nM after 48 h, and undergo pH-dependent release of Tofersen within the cytoplasm[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tofersen (0.25 mg/kg; i.v.; single dose) sodium combined with optimized FUS and microbubbles delivers 5-10% of the administered dose to mouse brain tissue, achieving >3.5-fold higher brain uptake than without FUS[5].
Tofersen (0.5 mg/kg; i.v.; once weekly; 9 weeks) sodium combined with FUS reduces SOD1 expression in targeted mouse brain cortex regions and preserves spinal cord motor neuron count without inducing neuroinflammation in G93A-SOD1 ALS mice[5].
Delivery of Tofersen (ISIS 333611) sodium to the CSF of SOD1G93A rats distributes to the brain and spinal cord, reduces spinal cord SOD1 mRNA and protein levels, and prolongs survival in this ALS model[6].
Tofersen (Intrathecal) sodium extends survival and improves muscle response function in transgenic rodent models of SOD1-mediated ALS[8].
Tofersen (Intrathecal) sodium lowers SOD1 protein concentrations in non-human primates[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B6SJL-Tg(SOD1*G93A)1Gur/J (equal numbers of male and female, pre-symptomatic 6 weeks old or symptomatic 12 weeks old)[2]
-
Dosage:42 nmol (~300 μg)
-
Administration:intracerebroventricular injection; single dose
-
Result:Extended median survival to 143 days (pre-symptomatic cohort) and 139 days (symptomatic cohort). Reduced SOD1 mRNA by 40%-60% in the cortex and cerebellum in both treatment cohorts.
-
Animal Model:B6.Cg Sod1G93A (G93A-SOD1) transgenic (9-week-old, male and female, ALS model)[6]
-
Dosage:0.5 mg/kg
-
Administration:i.v.; once weekly; 9 weeks
-
Result:Significantly reduced SOD1 fluorescence intensity in the FUS-exposed cerebral cortex compared to FUS-only or Tofersen-only control groups.
Showed no significant difference in SOD1 levels in non-FUS-exposed cerebellar regions.
Increased spinal cord motor neuron count significantly compared to both control groups.
Detected no significant increases in microglial (IBA1+ cell count) or astrocytic (GFAP fold change) activity in FUS-exposed brain regions, indicating no treatment-related neuroinflammation.
化学情報
-
CAS 番号 1898254-60-8
-
性状 Solid
-
分子量 7128 (free acid)
-
分子式 C230H298N72Na19O123P19S15
-
Color White to light yellow
-
SMILES
[Tofersen (sodium)]
-
別名
BIIB067 sodium; ISIS-SOD1Rx sodium; ISIS 333611 sodium
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Mass Spectrom
Characterisation of Antisense Oligonucleotides by Ion-Pair Reversed-Phase UHPLC-HRMS: Method development using Design of Experiments. [Abstract]2026 Apr;61(4):e70049. PMID: 41856548 -
Rapid Commun Mass Spectrom
Optimisation of Heated Electrospray Ionisation Parameters to Minimise In-Source Generated Impurities in the Analysis of Oligonucleotide Therapeutics. [Abstract]2025 Jul 15;39(13):e10033. PMID: 40181565
純度とドキュメンテーション
-
データシート (287 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2242 KB)
参考文献
[1]. Steffke C, et al. Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral Sclerosis. Ann Neurol. 2025;98(6):1318-1334. [Content Brief]
[2]. Weiss A, et al. RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice. Mol Ther. 2025;33(8):3917-3938. [Content Brief]
[3]. Miller TM, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099-1110. [Content Brief]
[4]. Miller TM, et al. Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. JAMA Neurol. 2026 Feb 1;83(2):115-125. [Content Brief]
[5]. Ediriweera GR, et al. Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapy. J Control Release. 2025;378:221-235. [Content Brief]
[6]. Miller TM, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013 May;12(5):435-42. [Content Brief]
[7]. Duan C, et al. Intrathecal administration of a novel siRNA modality extends survival and improves motor function in the SOD1G93A ALS mouse model. Mol Ther Nucleic Acids. 2024;35(1):102147. Published 2024 Feb 15. [Content Brief]
[8]. Miller T, et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020 Jul 9;383(2):109-119. [Content Brief]
[9]. Wiesenfarth M, et al. Effects of tofersen treatment in patients with SOD1-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access program. EClinicalMedicine. 2024;69:102495. Published 2024 Feb 15. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Tofersen sodium 関連分類
HY-132580A 関連分類
Powered by Bioz